LeonaBio, Inc. (LONA)
NASDAQ: LONA · Real-Time Price · USD
11.35
+1.33 (13.27%)
At close: Apr 2, 2026, 4:00 PM EDT
11.14
-0.21 (-1.85%)
After-hours: Apr 2, 2026, 6:56 PM EDT
LeonaBio Employees
LeonaBio had 26 employees as of December 31, 2024. The number of employees decreased by 41 or -61.19% compared to the previous year.
Employees
26
Change (1Y)
-41
Growth (1Y)
-61.19%
Revenue / Employee
n/a
Profits / Employee
-$4,061,885
Market Cap
105.96M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 26 | -41 | -61.19% | 26 | 0 |
| Dec 31, 2023 | 67 | 3 | 4.69% | 65 | 2 |
| Dec 31, 2022 | 64 | 29 | 82.86% | 63 | 1 |
| Dec 31, 2021 | 35 | 13 | 59.09% | 34 | 1 |
| Dec 31, 2020 | 22 | - | - | 20 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Biomea Fusion | 42 |
| Cardiff Oncology | 31 |
| Oncolytics Biotech | 28 |
| Genelux | 26 |
| AN2 Therapeutics | 21 |
| ProMIS Neurosciences | 8 |
| Aldeyra Therapeutics | 8 |
LONA News
- 8 days ago - LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer - GlobeNewsWire
- 3 months ago - Why Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition? - Benzinga
- 3 months ago - Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript - Seeking Alpha
- 3 months ago - Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment - GeekWire
- 3 months ago - Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million - GlobeNewsWire
- 7 months ago - Athira Pharma Announces Reverse Stock Split - GlobeNewsWire
- 11 months ago - Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit - GlobeNewsWire